Breast Cancer. Malignant neoplasm of breast
Conditions
Interventions
Intervention 1: Intervention group: Pioglitazone tablet of thiazolidinedione class osveh pharmacy prescribe one tablet daily with each meal for 6 monthes.Add to routine chemotherapy drugs based on Tax
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Women With Confirmed Pathologic Invasive Breast Cancer Represented by Mesaurable Visceral Metastases These Women should Aged at least 18 years old Performance Status(ECOG) should be 0-2 life Expectancy should be more than 3 months
Exclusion criteria
Exclusion criteria: Usage this group of drug during 12 months ago. Class III/IV Heart failure of New YORK HEART ASSOCIATION Hiv Positive, Pregnant or Breast Feading, Previous History or Active Bladder cancer NCI TOXICITY CRITERIA Grade 3,4 (VER 2.0) Total Billirubin more than 1.5 times upper limit Normal or liver enzymes more than 2.5 times upper limit Normal unless liver Metastasis make this limitation change to 5. Osteoporetic Patients (who = Tscore -2.5SD)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Radiologic Responses ( stable/partial/ complete/progressive). Timepoint: Before Intervention, Month 3, Month 6. Method of measurement: Recist criteria version 1.1.;Lesion Size. Timepoint: Before Intervention, Month 3, Month 6. Method of measurement: Ruler in ct scan software. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to progression. Timepoint: Month 3 and 6 from start study. Method of measurement: Watching.;Survival. Timepoint: Month 3 and 6 from start study. Method of measurement: watching.;Response Rate (percentage of patients whose cancer shrinks or disappears after treatment). Timepoint: Month 3 and 6 from start study. Method of measurement: Radiographic Response. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactReza Moghareabed
Esfahan University of Medical Sciences
Outcome results
None listed